Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Osteosarcoma: early-phase trial registry
3 of 14 indexed Recurrent Osteosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 3 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Recurrent Osteosarcoma: 14 US clinical trials tracked, 3 recruiting.
Recurrent Osteosarcoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-osteosarcoma
OPEN 3 | RECR 21% | LATE 0 | EARLY 14 | RANK #1230 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Cervical Adenocarcinoma (21% recruiting · 14 trials)
Recurrent Osteosarcoma lists 3 open slots (21% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Osteosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Osteosarcoma is recruiting below its size-band peers.
3 of 14 indexed trials (21.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Osteosarcoma research.
M.D. Anderson Cancer Center accounts for 4 of 14 trials (28.6%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Osteosarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 41 among the 14 trials that report a genuine target (sentinel values excluded). 11 of those (78.6%) plan for fewer than 100 participants.
-
Recurrent Osteosarcoma research is mostly interventional.
14 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
NCT04901702
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
M.D. Anderson Cancer Center
NCT05019703
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
Fred Hutchinson Cancer Center
NCT07227571
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
M.D. Anderson Cancer Center
NCT04668300
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Memorial Sloan Kettering Cancer Center
NCT02502786
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
NCT03598595
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
NCT03449108
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
NCT02357810
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
NCT02304458
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
National Cancer Institute (NCI)
NCT00030667
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
National Cancer Institute (NCI)
NCT02484443
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
Children's Oncology Group
NCT03320330
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
NCT01553539
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
NCT02097238
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Osteosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Osteosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Osteosarcoma page
14 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Recurrent Osteosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Recurrent Osteosarcoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Osteosarcoma condition card totals 14 registered trials; most-linked intervention Pharmacological Study; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.